The global radiodermatitis market size reached USD 514.8 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 668.0 Million by 2033, exhibiting a growth rate (CAGR) of 2.94% during 2025-2033.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024
|
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024
|
USD 514.8 Million |
Market Forecast in 2033
|
USD 668.0 Million |
Market Growth Rate 2025-2033 | 2.94% |
Radiodermatitis, or radiation dermatitis, refers to a skin condition caused due to radiation therapy used for the treatment of cancer. It generally occurs as a side effect during cancer treatment or after interventional radiology in patients with cancers of the breast, lungs, skin, neck, head or perineum region where the skin is part of the target field. Some of the commonly used products to treat radiodermatitis include topical antibiotics, corticosteroids, hydrophilic creams, hydrogel and hydrocolloid dressings, silicone-coated dressings, silver-leaf dressings, oral analgesics, and anti-inflammatory agents. In recent years, radiodermatitis treatment has gained traction as it helps reduce discomfort, minimize pain and prevent interruption in ongoing therapy while improving the overall quality of the patient’s life.
The widespread prevalence of cancer and the rising adoption of radiation therapy as a treatment option represent the primary factors driving the market growth. Besides this, the increasing geriatric population across the globe and the growing need to counter the adverse side effects of radiation therapy are augmenting the demand for radiodermatitis treatment. Additionally, numerous governing and non-governing agencies are taking favorable initiatives to spread awareness regarding the available radiodermatitis treatment and management products. This, in confluence with the rising public and private investments in the ongoing research and development (R&D) activities in the field of life sciences, is catalyzing the market growth. Furthermore, the leading players are focusing on developing innovative product variants to expand their product portfolio and gain a competitive edge. Moreover, the rising number of clinical trials, favorable government policies, increasing consumer expenditure capacities, improving healthcare infrastructure and easy availability of generic drugs are some of the other factors creating a positive market outlook.
IMARC Group provides an analysis of the key trends in each sub-segment of the global radiodermatitis market report, along with forecasts at the global, regional and country level from 2025-2033. Our report has categorized the market based on product and distribution channel.
Breakup by Product:
Breakup by Distribution Channel:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being 3M Company, Bausch Health Companies Inc., Bayer AG, BMG PHARMA S.p.A., Charles River Laboratories International Inc., ConvaTec Group plc, Helsinn Healthcare SA, ICON plc, Integra LifeSciences, Mölnlycke Health Care AB and Stratpharma AG.
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Million USD |
Segment Coverage | Product, Distribution Channel, Region |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | 3M Company, Bausch Health Companies Inc., Bayer AG, BMG PHARMA S.p.A., Charles River Laboratories International Inc., ConvaTec Group plc, Helsinn Healthcare SA, ICON plc, Integra LifeSciences, Mölnlycke Health Care AB and Stratpharma AG |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
The global radiodermatitis market was valued at USD 514.8 Million in 2024.
We expect the global radiodermatitis market to exhibit a CAGR of 2.94% during 2025-2033.
The sudden outbreak of the COVID-19 pandemic had led to postponement of elective radiodermatitis treatments to reduce the risk of the coronavirus infection upon hospital visits or interaction with healthcare professionals.
The rising demand for radiodermatitis treatment to reduce discomfort, minimize pain, and prevent interruption in ongoing radiation therapy, which is used to treat cancer, is primarily driving the global radiodermatitis market.
Based on the product, the global radiodermatitis market has been segmented into topical, oral, and dressings. Currently, topical holds the majority of the total market share.
Based on the distribution channel, the global radiodermatitis market can be divided into hospital pharmacy, retail pharmacy, and online pharmacy. Among these, retail pharmacy exhibits a clear dominance in the market.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where Asia-Pacific currently dominates the global market.
Some of the major players in the global radiodermatitis market include 3M Company, Bausch Health Companies Inc., Bayer AG, BMG PHARMA S.p.A., Charles River Laboratories International Inc., ConvaTec Group plc, Helsinn Healthcare SA, ICON plc, Integra LifeSciences, Mölnlycke Health Care AB, and Stratpharma AG.